Supplementary Figure 5 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

作者：Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Eleonora Gariazzo, Francesco Mantuano, Edoardo Garbo, Mihaela Aldea, Valentina Santo, Don L. Gibbons, Hai T. Tran, Francesco Paoloni, Guilherme Rossato de Almeida, Giulio Metro, Andrea De Giglio, Francesco Gelsomino, Xinan Wang, Marcello Tiseo, Julia Rotow, Andrea Ardizzoni, J. Jack Lee, Mark M. Awad, Alfredo Addeo, Lingzhi Hong, Marcelo V. Negrão, Pasi A. Jänne, John V. Heymach, Jianjun Zhang, Biagio Ricciuti, Xiuning Le · 年份：2025 · DOI：10.1158/1078-0432.30618004 · 研究领域：Melanoma and MAPK Pathways、Lung Cancer Treatments and Mutations、Fibroblast Growth Factor Research

<p>Supplementary Figure 5</p>